Your browser doesn't support javascript.
loading
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Zeidan, A M; Sekeres, M A; Garcia-Manero, G; Steensma, D P; Zell, K; Barnard, J; Ali, N A; Zimmerman, C; Roboz, G; DeZern, A; Nazha, A; Jabbour, E; Kantarjian, H; Gore, S D; Maciejewski, J P; List, A; Komrokji, R.
Afiliación
  • Zeidan AM; Department of Internal Medicine, Section of Hematology, Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA.
  • Sekeres MA; Leukemia Program, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
  • Garcia-Manero G; Department of leukemia, MD Anderson Cancer Center, Houston, TX, USA.
  • Steensma DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Zell K; Leukemia Program, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
  • Barnard J; Leukemia Program, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
  • Ali NA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Zimmerman C; Leukemia Program, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
  • Roboz G; Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA.
  • DeZern A; Department of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
  • Nazha A; Leukemia Program, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
  • Jabbour E; Department of leukemia, MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian H; Department of leukemia, MD Anderson Cancer Center, Houston, TX, USA.
  • Gore SD; Department of Internal Medicine, Section of Hematology, Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA.
  • Maciejewski JP; Leukemia Program, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
  • List A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Komrokji R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Leukemia ; 30(3): 649-57, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26464171
Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are standard therapies for higher-risk (HR)-MDS, the relative prognostic performance of existing prognostic tools among patients with HR-MDS receiving azanucleoside therapy is unknown. In the MDS Clinical Research Consortium database, we compared the prognostic utility of the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R), MD Anderson Prognostic Scoring System (MDAPSS), World Health Organization-based Prognostic Scoring System (WPSS) and the French Prognostic Scoring System (FPSS) among 632 patients who presented with HR-MDS and were treated with azanucleosides as the first-line therapy. Median follow-up from diagnosis was 15.7 months. No prognostic tool predicted the probability of achieving an objective response. Nonetheless, all five tools were associated with overall survival (OS, P=0.025 for the IPSS, P=0.011 for WPSS and P<0.001 for the other three tools). The corrected Akaike Information Criteria, which were used to compare OS with the different prognostic scoring systems as covariates (lower is better) were 4138 (MDAPSS), 4156 (FPSS), 4196 (IPSS-R), 4186 (WPSS) and 4196 (IPSS). Patients in the highest-risk groups of the prognostic tools had a median OS from diagnosis of 11-16 months and should be considered for up-front transplantation or experimental approaches.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azacitidina / Síndromes Mielodisplásicos / Antineoplásicos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azacitidina / Síndromes Mielodisplásicos / Antineoplásicos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos